BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Data were gathered from clinical records with approval of CCERC institutional management.<h4>Results</h4>One hundred and forty-nine patients with Ph+ CML were included; 20.1% were COVID-19-positive; 56% were male; mean age was 46 years; 81% were receiving imatinib, with a mean treatment duration of 6 years; 55% achieved a BCR -ABL molecular response ≤ 0.1% (IS).